Friedlander, M., Chan, J. K., Java, J., Armstrong, D. K., Markman, M., Herzog, T. J., … Copeland, L. J. (2018). Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients. In Journal of Clinical Oncology (Vol. 36, pp. 5556–5556). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5556

Friedlander, Michael, John K. Chan, Jim Java, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, et al. “Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.” In Journal of Clinical Oncology, 36:5556–5556. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5556.

Friedlander M, Chan JK, Java J, Armstrong DK, Markman M, Herzog TJ, et al. Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5556–5556.

Friedlander, Michael, et al. “Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5556–5556. Crossref, doi:10.1200/jco.2018.36.15_suppl.5556.

Friedlander M, Chan JK, Java J, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes FJ, Secord AA, Bonebrake AJ, Rose PG, Tewari KS, Mannel RS, Lentz SS, Geller MA, Copeland LJ. Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5556–5556.